483 related articles for article (PubMed ID: 28356730)
1. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
Waschki B; Watz H; Holz O; Magnussen H; Olejnicka B; Welte T; Rabe KF; Janciauskiene S
Int J Chron Obstruct Pulmon Dis; 2017; 12():981-987. PubMed ID: 28356730
[TBL] [Abstract][Full Text] [Related]
2. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
[TBL] [Abstract][Full Text] [Related]
3. Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
Iida K; Tani S; Atsumi W; Yagi T; Kawauchi K; Matsumoto N; Hirayama A
Coron Artery Dis; 2017 Nov; 28(7):577-587. PubMed ID: 28692480
[TBL] [Abstract][Full Text] [Related]
4. Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD.
Urban MH; Eickhoff P; Funk GC; Burghuber OC; Wolzt M; Valipour A
Int J Chron Obstruct Pulmon Dis; 2017; 12():169-176. PubMed ID: 28115840
[TBL] [Abstract][Full Text] [Related]
5. Adipocytokines in primary antiphospholipid syndrome: potential markers of low-grade inflammation, insulin resistance and metabolic syndrome.
Rodrigues CE; Vendramini MB; Bueno C; Bonfá E; de Carvalho JF
Clin Exp Rheumatol; 2012; 30(6):871-8. PubMed ID: 22935544
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein levels in stable COPD patients: a case-control study.
Silva DR; Gazzana MB; Knorst MM
Int J Chron Obstruct Pulmon Dis; 2015; 10():1719-25. PubMed ID: 26357470
[TBL] [Abstract][Full Text] [Related]
7. Positive correlation of airway resistance and serum asymmetric dimethylarginine level in COPD patients with systemic markers of low-grade inflammation.
Tajti G; Gesztelyi R; Pak K; Papp C; Keki S; Szilasi ME; Mikaczo A; Fodor A; Szilasi M; Zsuga J
Int J Chron Obstruct Pulmon Dis; 2017; 12():873-884. PubMed ID: 28352168
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.
Irish AB
Metabolism; 1997 Jan; 46(1):36-40. PubMed ID: 9005966
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia correlates with systemic inflammation in COPD.
Byun MK; Cho EN; Chang J; Ahn CM; Kim HJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():669-675. PubMed ID: 28255238
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.
Targher G; Bertolini L; Scala L; Zoppini G; Zenari L; Falezza G
Diabet Med; 2005 Oct; 22(10):1354-8. PubMed ID: 16176196
[TBL] [Abstract][Full Text] [Related]
11. Skin condition and its relationship to systemic inflammation in chronic obstructive pulmonary disease.
Majewski S; Pietrzak A; Tworek D; Szewczyk K; Kumor-Kisielewska A; Kurmanowska Z; Górski P; Zalewska-Janowska A; Piotrowski WJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2407-2415. PubMed ID: 28860735
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
Gumus A; Altintas N; Cinarka H; Kirbas A; Hazıroglu M; Karatas M; Sahin U
Int J Chron Obstruct Pulmon Dis; 2015; 10():357-65. PubMed ID: 25709430
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease.
Jiang Y; Xiao W; Zhang Y; Xing Y
Respirology; 2010 Aug; 15(6):939-46. PubMed ID: 20624254
[TBL] [Abstract][Full Text] [Related]
14. Systemic inflammation in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention.
Zhang XL; Chi YH; Wang le F; Wang HS; Lin XM
Respirology; 2014 Jul; 19(5):723-9. PubMed ID: 24750361
[TBL] [Abstract][Full Text] [Related]
15. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
Xiao W; Tong WL; Ma DD
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
[TBL] [Abstract][Full Text] [Related]
16. Dynamic pulmonary hyperinflation and low grade systemic inflammation in stable COPD patients.
Gatta D; Aliprandi G; Pini L; Zanardini A; Fredi M; Tantucci C
Eur Rev Med Pharmacol Sci; 2011 Sep; 15(9):1068-73. PubMed ID: 22013730
[TBL] [Abstract][Full Text] [Related]
17. COPD assessment test score and serum C-reactive protein levels in stable COPD patients.
Kang HK; Kim K; Lee H; Jeong BH; Koh WJ; Park HY
Int J Chron Obstruct Pulmon Dis; 2016; 11():3137-3143. PubMed ID: 27994452
[TBL] [Abstract][Full Text] [Related]
18. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
Mertens I; Ballaux D; Funahashi T; Matsuzawa Y; Van der Planken M; Verrijken A; Ruige JB; Van Gaal LF
Thromb Haemost; 2005 Dec; 94(6):1190-5. PubMed ID: 16411393
[TBL] [Abstract][Full Text] [Related]
19. Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.
Wu Y; Shen Y; Zhang J; Wan C; Wang T; Xu D; Yang T; Wen F
Int J Chron Obstruct Pulmon Dis; 2015; 10():2405-12. PubMed ID: 26609227
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
